Apellis Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Apellis Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2023.
  • Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$57.4M, a 59% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$250M, a 58.7% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$529M, a 18.9% increase from 2022.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$652M, a 12.6% increase from 2021.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$746M, a 116% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$529M +$124M +18.9% Jan 1, 2023 Dec 31, 2023 10-K/A 2024-02-29
2022 -$652M +$94.2M +12.6% Jan 1, 2022 Dec 31, 2022 10-K/A 2024-02-29
2021 -$746M -$401M -116% Jan 1, 2021 Dec 31, 2021 10-K/A 2024-02-29
2020 -$345M -$40.2M -13.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 -$305M -$177M -139% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$128M -$76.5M -150% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$51M -$23.9M -88% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$27.1M +$19.4M +41.7% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-26
2015 -$46.5M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.